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Background: Patients with pancreatic cancer have a poor prognosis apart from the few suitable for surgery. Photodynamic
therapy (PDT) produces localised tissue necrosis but previous studies using the photosensitiser meso-tetrahydroxyphenylchlorin
(mTHPC) caused prolonged skin photosensitivity. This study assessed a shorter acting photosensitiser, verteporfin.
Methods: Fifteen inoperable patients with locally advanced cancers were sensitised with 0.4mg kg 1 verteporfin. After 60–90min,
laser light (690 nm) was delivered via single (13 patients) or multiple (2 patients) fibres positioned percutaneously under computed
tomography (CT) guidance, the light dose escalating (initially 5 J, doubling after each three patients) until 12mm of necrosis was
achieved consistently.
Results: In all, 12mm lesions were seen consistently at 40 J, but with considerable variation in necrosis volume (mean volume
3.5 cm3 at 40 J). Minor, self-limiting extrapancreatic effects were seen in multifibre patients. No adverse interactions were seen in
patients given chemotherapy or radiotherapy before or after PDT. After PDT, one patient underwent an R0 Whipple’s
pancreaticoduodenectomy.
Conclusions: Verteporfin PDT-induced tumour necrosis in locally advanced pancreatic cancer is feasible and safe. It can be
delivered with a much shorter drug light interval and with less photosensitivity than with older compounds.
INTRODUCTION
Pancreatic cancer. Adenocarcinoma of the pancreas is one of the
top 10 leading causes of cancer deaths. In the United Kingdom,
B8000 people are diagnosed with the disease each year. Surgical
resection is the only chance of cure and is only possible in a
minority of subjects. Even after resection, the median survival is
only 10–20 months and only 12–35% of resected patients survive 5
years or more (Kinsella et al, 2008; Eeson et al, 2012; He et al, 2013;
Turrini et al, 2013).
Palliative chemotherapy has been shown to improve both
quality of life and survival in advanced pancreatic cancer,
when compared with best supportive care. Combination regimens
including FOLFIRINOX (oxaliplatin, irinotecan, fluorouracil, and
leucovorin) have shown improved outcome compared with
gemcitabine monotherapy (median overall survival 11.1 vs 6.8
months; hazard ratio (HR)¼ 0.57; Po0.001) (Conroy et al, 2011),
while a phase III study of weekly intravenous albumin-bound
paclitaxel (nab-paclitaxel) plus gemcitabine resulted in a signifi-
cantly higher overall survival compared with gemcitabine mono-
therapy (8.5 vs 6.7 months; HR¼ 0.72; Po0.001), with survival
rates of 35% vs 22% at 1 year (Von Hoff et al, 2013). The UK
GEM-CAP trial reported a median survival in the combination
capecitabineþ gemcitabine group of 7.1 months compared with
6.2 months in those who received gemcitabine alone, with 1-year
overall survival rates of 24.3% vs 22% (HR¼ 0.86; P¼ 0.077)
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(Cunningham et al, 2009). Trials of monoclonal antibodies and
small molecule inhibitors have had limited success (Moore et al,
2007; von Wichert et al, 2008; Kindler et al, 2010). Overall, the
long-term prognosis of the disease is poor with a 1-year survival
rate of 15–39% (Sant et al, 2009; Cronin-Fenton et al, 2011; Gong
et al, 2011; Kuroda et al, 2013; Luo et al, 2013). For locally
advanced disease, the median survival is 6–10 months, although for
those with metastatic disease at presentation, the median survival
may be as low as 3–6 months.
Given these dismal results, a minimally invasive treatment
capable of local destruction of tumour tissue with low morbidity
may have a place in the treatment of unresectable disease.
Photodynamic therapy. Photodynamic therapy (PDT) is a way of
producing localised tissue necrosis with light (most conveniently
from a low-power laser), after prior administration of a photo-
sensitising agent. It causes tissue necrosis by a non-thermal
cytotoxic effect, thought to be mediated by singlet oxygen. As the
biological effect is photochemical, not thermal, there is little
damage to connective tissues such as collagen and elastin so
helping to preserve the mechanical integrity of tissues, particularly
hollow organs (Barr et al, 1987).
A pilot clinical trial of PDT in pancreatic cancer (the first in the
world), using meso-tetrahydroxyphenylchlorin (mTHPC), was
published by our group in 2002 (Bown et al, 2002). Sixteen
patients with locally advanced cancers in the head of the pancreas
were treated with PDT using light delivered directly into the
tumours by laser fibres inserted through needles positioned
percutaneously through the anterior abdominal wall under
ultrasound and computed tomography (CT) guidance. All patients
were found to have areas of tumour necrosis (up to a volume of
60 cm3) on CT within a few days of PDT. There was no treatment-
related mortality and all but two patients were discharged from
hospital within 10 days. It was concluded that PDT could produce
necrosis in pancreatic cancers with an acceptable morbidity,
although care was required for tumours invading the duodenal wall
or involving the gastroduodenal artery. The median survival after
PDT was 9.5 months (range 4–30, one patient alive at 31 months;
median 12.5 months after treatment).
Verteporfin is a second-generation photosensitiser that has been
licensed for 410 years for the treatment of age-related macular
degeneration (Wu and Murphy, 1999). There has been consider-
able interest in its potential for the management of ocular tumours,
but relatively little investigation into its value for other oncological
indications, aside from pre-clinical studies in oesophagus and
vertebral breast metastases (Panjehpour et al, 2002; Lo et al, 2012).
Compared with the first-generation photosensitiser, mTHPC,
the key attraction of verteporfin is its rapid clearance by excretion
in bile. The peak tissue concentration of verteporfin is seen within
an hour or two of administration, so light can be delivered with a
much shorter drug light interval than the 2–4 days required with
mTHPC (Lin et al, 1998; Fingar et al, 1999); and the period of skin
photosensitivity is typically only 24 h (Houle and Strong, 2002a, b).
In contrast, patients treated with mTHPC must avoid bright
daylight for 7 days and avoid bright sunlight for 1 month. Pre-clinical
studies of the pharmacokinetics and mechanisms of tissue killing
with verteporfin have been developed extensively in a number of
cancer models and show that while it has been largely considered a
vascular damaging photosensitiser, it also has a potent cellular
killing efficacy that is present when given sufficient time for
transvascular permeation and diffusion in the tumour tissue (Chen
et al, 2003, 2005a, 2005b; Samkoe et al, 2010; Glidden et al, 2012).
Another advantage of verteporfin is its strong absorption at
690 nm, a wavelength at which light penetrates tissue better than at
the shorter red wavelength absorption peaks of mTHPC and
porfimer sodium. It has a weaker absorption peak at 630 nm, which
was previously used pre-clinically in the treatment of the canine
oesophagus, but the deeper penetration and the stronger absorp-
tion at 690 nm are more appropriate for treating tumours in solid
organs like the pancreas (Panjehpour et al, 2002). The safety of
interstitial PDT using verteporfin was investigated by our group in
the Syrian golden hamster (Ayaru et al, 2007). Light doses of 10
and 25 J cm 2 were safe in the hamster pancreas and liver,
respectively, and produced lesions of between 3 and 10mm in
diameter. At these doses, there was no evidence of perforation or
obstruction of hollow organs. In a subsequent study in a xenograft
model of pancreatic cancer, the extent of verteporfin PDT-induced
necrosis was found to be dependent on the aggressiveness of the
tumour; at the same light dose, more aggressive AsPC-1 tumours
showed a greater amount of necrosis in response to PDT than less
aggressive PANC-1 tumours (Samkoe et al, 2010).
These results were sufficient to achieve regulatory approval to
conduct a phase I/II study of verteporfin PDT in locally advanced
unresectable pancreatic adenocarcinoma (VERTPAC-01).
MATERIALS AND METHODS
Fifteen patients were treated with verteporfin PDT to confirm its
general safety profile, to determine appropriate treatment para-
meters, and to confirm the safety of PDT if given either before or
after conventional palliative chemotherapy or radiotherapy.
The study consisted of two parts. The first part was a single fibre
dose escalation study to establish how the extent of necrosis related
to the delivered light dose and to choose a suitable light dose for
the second, multifibre part of the study.
Patients were eligible if they had a histological or cytological
diagnosis of pancreatic adenocarcinoma, proven locally advanced
disease confirmed to be unsuitable for surgery at multidisciplinary
review, and adequate biliary drainage (serum bilirubin o2.5
upper limit of normal). Participants were staged using a pancreatic
protocol CT and chest X-ray or CT within 28 days before PDT. It
was mandatory for patients to give informed consent, have a
negative pregnancy test if appropriate, and an ECOG performance
status of 0–2. Exclusion criteria were porphyria, locally advanced
disease involving 450% circumference of the duodenum or a
major artery (e.g., hepatic and gastroduodenal) within the treatment
area, metastatic disease, or ECOG performance status 42.
After diagnosis and entry criteria were confirmed, patients
received intravenous verteporfin 0.4mg kg 1 body weight, and
prophylactic oral ciprofloxacin 500mg, which was continued for
24 h after the procedure (three doses in total). Patients were
sedated with midazolam and fentanyl and the anterior abdominal
wall was infiltrated with local anaesthetic. The tumour was then
punctured with a 19-gauge hollow metal needle (Cook Group Inc.,
Bloomington, IN, USA) under CT guidance by an experienced
radiologist. A 0.4-mm core diameter optical fibre with a 1-cm long
diffuser tip was inserted through to the tip of the needle and the
needle pulled back 10mm over the fibre, leaving the diffuser tip in
direct contact with the target tumour. An OpadL 690-nm, 0.3-W
diode laser was calibrated to deliver 150mWcm 1 along the
diffuser tip of the fibre. The tumour was illuminated between 60
and 90min after verteporfin administration. The aim of the study
was to establish the light dose required to safely produce a zone of
necrosis of at least 12mm in diameter in a group of three patients
treated with each light dose, using a single laser fibre and the
chosen dose of verteporfin of 0.4mg kg 1. The starting light dose
was 5 J (150mW for 33 s). As long as there was no evidence of
unacceptable toxicity, the light dose was doubled after each group
of three patients until the target size of necrosis was achieved in all
three patients in a group, which was at 40 J. At this point, two
further patients were treated, one with two fibres (both with 1-cm
diffuser tips) and one with three (all with 2-cm diffuser tips).
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Patients remained in subdued lighting for 24 h after verteporfin
injection (or 48 h in patients with underlying liver disease),
followed by re-adaptation to indirect sunlight for increasing
periods during the morning and late afternoon of the next day.
Bright indoor light was permitted after 24 h (72 h for underlying
liver disease) and exposure to direct sunlight allowed after 48 h
(96 h for underlying liver disease).
Patients had daily clinical review to assess for potential
complications, including abdominal pain, pancreatitis, perforation,
biliary obstruction, paralytic ileus, and sepsis. On day 5, a repeat
pancreatic protocol CT was performed. The scans were reviewed
independently by two consultant radiologists to measure the
maximum diameter of PDT-induced necrosis, particularly in the
patients treated with a single fibre; and to assess whether the target
size of lesion had been achieved. In all patients, the total volume of
PDT necrosis was estimated by volume rendering after segmenta-
tion on the CT scans.
Treatment-related toxicity was assessed at discharge and at each
subsequent follow-up visit. All toxicities were graded according to
the National Cancer Institute Common Terminology Criteria for
Adverse Events (version 3.0) and were reported to the UCL/UCLH
Joint Research Office for documentation. The maximum grade was
used for each patient and each toxicity type. The sponsor
(University College London) was responsible for monitoring of
the trial and provided the regulatory authorities REC (trial
reference 06/Q0502/70) and MHRA (trial reference 2006-004097-28)
with annual safety reports as well as reporting of any suspected
unexpected serious adverse reactions.
An interval CT was performed 4 weeks after PDT, following
which patients were able to commence appropriate oncological
treatment if they wished. Further treatment with radiotherapy,
chemotherapy, and/or retreatment with verteporfin PDT (at the
highest safe evaluated dose) was at the discretion of their
oncologist and the investigators. Patients continued to be followed
for survival data. The primary end point for each patient in the
single fibre study was the mean diameter of necrosis achieved
around the treatment fibre for a given light dose. Secondary end
points were the total volume of PDT necrosis for each treatment,
safety, toxicity, tumour response, and overall survival.
RESULTS
A total of 58 patients were screened for the trial. Fifteen fulfilled
the entry criteria and were treated (11 male and 4 female; median
age 59 (range 47–78)). In one patient, it was concluded that there
was too much necrosis present in the tumour before PDT for it to
be possible to assess the volume of necrosis induced by the PDT
effect, so this patient was excluded from the quantitative analysis,
but included in the safety considerations. The median ECOG
performance status was 0 (range 0–2).
All patients had proven pancreatic adenocarcinoma on
histology or cytology and had a staging CT within 4 weeks of
undergoing treatment, which confirmed locally advanced disease,
and agreed by a multidisciplinary meeting to be unsuitable for
resection surgery. Baseline tumour size was radiologically asses-
sable in 13 patients on the pre-treatment CT and the median
diameter in maximal dimension was 40mm (range 20–62mm).
Thirteen tumours orginated in the head of the pancreas and two in
the body.
All patients were treated according to the protocol; needle
placement and light delivery were technically successful in all
patients. Representative CT scans of a patient before treatment
showing the fibre positioned in the tumour and 5 days later are
shown in Figure 1. Thirteen patients were treated in the dose
escalation phase of the study and treated with a single laser fibre.
Of these, three treatments were carried out at each of the 5, 10, 20,
and 40 J cm 1 settings; a further patient was later also treated at
40 J cm 1 as it was an earlier patient in this group in which it was
not possible to assess the extent of PDT necrosis due to pre-
existing necrosis. In the second (multiple fibre) phase of the trial,
two patients were treated (one with two and one with three fibres)
using 40 J cm 1. In the patient treated with three fibres, 20-mm
diffuser tip fibres were used. In all other patients 10-mm diffuser
tip fibres were used. One patient in the 20-J group was treated on a
second occasion 3.5 months after the first PDT with a single fibre
delivering 40 J.
No necrosis was seen in the patients treated with 5 J. At 10 J, the
diameter of one lesion was over 12mm, at 20 J, two were over
12mm and at 40 J, all three were over 12mm, so reaching the
stopping point defined in the protocol.
Necrosis volumes were determined for all patients (excluding
the one with spontaneous necrosis before PDT) using volume
rendering after segmentation of the zone of necrosis on the scan
slices (Figure 2A–C), and are shown in Figure 2D. The mean
volume of necrosis was 0.46 cm3 for the three patients treated at
10 J, 1.14 cm3 at 20 J, and 3.48 cm3 at 40 J. In the two patients
treated with multiple fibres, the necrosis volumes were 5.3 and
23.2 cm3. The measurements of tumour size before PDT together
with the treatment parameters, and volume and mean diameter of
necrosis on individual patients are shown in Table 1.
Adverse events. In patients treated with a single fibre, three had
mild to moderate abdominal pain shortly after PDT. In two
patients this settled on analgesics, although pain persisted in one
(the patient who had necrotic tumour before PDT). Another
patient had a transient rise in amylase to 234 IU l 1 but did not
complain of abdominal pain. In all others, the level did not rise
above the upper limit of normal (90 IU l 1). One patient had mild
diarrhoea shortly after PDT which settled spontaneously, and
another developed persisting steatorrhoea 2 weeks after PDT,
neither of which was thought to be directly related to the
treatment. No patient had any problems with photosensitivity and
there was no evidence of early duodenal obstruction. No patients
had overt evidence of bleeding or a fall in haemoglobin.
Both of the patients treated with multiple fibres had evidence on
CT of inflammatory change occurring anterior to the pancreas
along the needle tract. Both were kept nil by mouth in hospital for
observation, although neither had any change in their clinical
state and were discharged at 5–10 days after treatment. The
inflammatory change was not associated with development of
intraabdominal collections or sepsis, and had resolved by the time
of the day 28 CT.
Follow-up. On RECIST criteria, 11 of the 13 patients in whom the
tumour size was assessable pre- and post-treatment had stable
disease at 1 month, although 2 of the remainder developed liver
metastases at this time. In six patients, stable disease was
maintained at 3 months.
Seven adverse events occurred more than 28 days after PDT,
which were deemed to be related to tumour progression.
Figure 1. CT scans from patient 13 undergoing verteporfin PDT. The
image on the left shows a baseline contrast-enhanced CT with a low
attenuation mass in the head of the pancreas. The centre image shows
percutaneous needle placement into the tumour. The image on the
right shows the day 5 post PDT contrast-enhanced CT with a 2.67-cm3
zone of necrosis in the region of the pancreatic head (arrowed).
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Five patients developed obstructive jaundice secondary to stent
dysfunction and were managed by ERCP and stent change as part
of our normal practice. Two patients developed duodenal
obstruction, which was managed by endoscopic insertion of self-
expanding metal stents. No other oncological treatments were
given within 1 month of PDT. Eight patients received chemother-
apy, radiotherapy, or both before PDT and twelve received other
oncological treatment following PDT (Table 2). The Kaplan–Meier
survival curve is shown in Figure 3. As of September 2013, all but
one patient in the study had died (median survival 8.8 months after
PDT, range 3.1–25.9 months; median survival from diagnosis 15.5
months, range 4.0–33.6 months).
The one surviving patient (patient 7) was previously enrolled in
the PACER trial and treated with conformal radiotherapy and
cetuximab 5 months before treatment with PDT at the 20-J energy
setting. He was considered to be inoperable on his pre-PDT CT
scan as this showed tumour tissue abutting the medial aspect of the
superior mesenteric artery (Figure 4A). However, on his scan taken
28 days after PDT, the lesion appeared to have contracted and was
no longer directly involving the artery (Figure 4B). As a
consequence, he was then deemed to have surgically resectable
disease and went on to have a Whipple’s pancreaticoduodenect-
omy. The surgical specimen showed perineural invasion of tumour,
but no lymphovascular or lymph-node involvement and the
resection margins were clear of tumour (R0 resection). There was
dense fibrosis throughout the resected pancreatic tissue with
scattered nests of malignant cells. However, there was a central
paucicellular area, corresponding to where the light for PDT had
been delivered (Figure 5). This zone was smaller than the area of
necrosis documented on CT a few days after PDT, consistent with
healing as surgery was undertaken 5 weeks after PDT. The patient
showed no evidence of recurrence until 36 months after PDT when
he was found to have an anterior omental nodule on imaging and
was commenced on palliative chemotherapy.
DISCUSSION
Photodynamic therapy for cancer of the pancreas was first
described in 2002 (Bown et al, 2002). That study showed that
percutaneous, image guided PDT with the photosensitiser mTHPC
(meso-tetrahydroxyphenyl chlorin, temoporfin, Foscan) could
produce necrosis in pancreatic cancers with an acceptable level
of morbidity. Meso-tetrahydroxyphenyl chlorin is a powerful
photosensitiser, but has the considerable disadvantage that it is
necessary to wait up to 4 days after giving the drug before
delivering the light. It also causes prolonged photosensitivity of
skin and eyes to light and patients need to stay out of bright
sunlight for up to a month. The aim of this current study was to
assess the safety and efficacy of a new generation photosensitiser,
using a formal dose escalation approach to establish how the extent
of necrosis varied with the delivered light dose. No serious adverse
effects were seen using PDT either before or after other oncological
treatments, although our protocol dictated an interval of at least a
month between treatments.
As expected, the volume of necrosis broadly increased with the
amount of energy delivered to the tumour but, as shown in
Figure 2D, there was considerable variation in the volume of
necrosis within each energy band. These data show that it is
difficult to predict the extent of necrosis based just on the dose of
photosensitiser, the drug light interval, and the light dose. There
may be differences in the pharmacokinetics of the photosensitiser
between patients, but it is more likely that there are real-time
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Figure 2. Necrosis measurements following verteporfin PDT in patient 4. (A) A single axial slice of the pancreas from the post-treatment
CT scans. The arrow indicates the area of necrosis within the pancreas. (B) The same slice showing segmentation of the necrotic tissue in pink.
(C) Volume rendering of segmentation of the necrotic zone. (D) The volume of the necrotic tissue region is shown for each patient in the study, as
determined from the segmentation of the post-treatment CT scans. Total energy delivered is shown for each patient. For patient 14, two fibres of
1-cm diffuser length each delivering 40 J cm 1 were used. For patient 15, three fibres of 2-cm diffuser length each delivering 40 J cm 1 were
used. Patient 12 is not included in this figure as necrosis was present before treatment and therefore the effect of treatment could not be assessed.
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variations related to the tissue and vascular perfusion around a
fibre positioned interstitially that influence how deeply the light
penetrates.
In both of the patients treated with multiple fibres, the first
follow-up CT scan at day 5 showed unexpected inflammation
anterior to the pancreas. Investigation of this ex vivo demonstrated
that the likely explanation lay in a problem with the fibres. When
the fibres were examined in the physics laboratory, it was apparent
that the emission of light from the fibres was not limited to the
diffuser tip but extended for up to about 1 cm proximal to the tip.
The light intensity in this region was considerably less than in the
intended emission zone, however, with multiple fibres the over-
lapping fields resulted in this area receiving a higher light dose than
in patients treated with a single fibre and the tissue in this region
would not be expected to be immune from a PDT effect. In the
mTHPC paper (Bown et al, 2002), an area of normal pancreas was
treated inadvertently in one patient when a fibre slipped after
positioning. A clear area of necrosis was seen in the normal
pancreas, but this healed safely without sequelae, as demonstrated
on CT after 1 month. These observations further support previous
reports of how PDT is not highly tumour selective, but that treated
areas in a range of normal tissues can heal safely without a
significant loss of structure or function (Anand et al, 2012;
Bown, 2013).
Table 1. Details of patients and treatments
Patient
number Sex/age
Baseline
tumour
diam.
(cm)
Total
energy
(J)
Mean
necrosis
diameter
on day 5
CT (cm)
Necrosis
volume
on day 5
CT (cm3)
1 M/59 4.0 5 0 0
2 M/76 4.4 5 0 0
3 M/62 N/Aa 5 0 0
4 F/54 3.8 10 1.4 0.96
5 M/63 2.8 10 0.5 0.43
6 M/68 4.2 10 0 0
7 M/47 3.8 20 0.5 0.34
8 M/54 4.0 20 1.9 2.37
9 F/56 3.5 20 1.8 0.72
10 F/59 N/Aa 40 2.2 5.17
11 M/57 3.8 40 2.1 2.61
12 M/78 6.5 40 N/A N/Ab
13 F/69 2.0 40 2.1 2.67
14 M/56 3.7 80 3.1 5.3
15 M/65 5.3 240 4.1 23.2
Abbreviations: CT¼ computed tomography; F¼ female; M¼male; PDT¼photodynamic
therapy. The diameter of necrosis given is the mean of the extent of necrosis in the x, y, and
z planes. All patients were treated with a single optical fibre with a 1-cm diffuser tip except
patient 14 (two fibres, each with a 1-cm diffuser tip, 40 J cm 1) and patient 15 (three fibres,
each with a 2-cm diffuser tip, 40 J cm 1).
aIn patients 3 and 10, the margins were not well enough defined to measure the
tumour size.
bIn patient 12, there was tumour-related necrosis before PDT so the effect of PDT could not
be assessed.
Table 2. Oncological treatment given before and after PDT
All Female Male
No prior treatment 7 1 6
Prior chemotherapy 3 0 3
Prior chemo-radiotherapy 3 1 2a
Prior immunotherapy 2b 2 0
No treatment after PDT 3 1 2
Chemotherapy after PDT 8 2 6
Chemo-radiotherapy after PDT 1 0 1
Immunotherapy after PDT 2b 1 1
Whipple’s pancreaticoduodenectomyþ chemotherapy
after PDT
1 0 1
Abbreviation: PDT¼photodynamic therapy.
aOne patient was previously enrolled in the PACER Trial (Radical radiotherapy with
concurrent Cetuximab monoclonal antibody therapy).
bFour patients were enrolled in the Telovac Trial (GV1001 vaccine vs gemcitabineþ
capecitabine in a phase III trial for advanced and metastatic pancreatic cancer). No
oncological treatment was given less than a month before or after PDT .
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Figure 3. Kaplan–Meier curve showing the cumulative survival from
treatment with PDT in all patients.
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Figure 4. CT scan from patient 7 who had a successful Whipple’s
resection following PDT. (A) Image from CT before PDT showing
tumour abutting the superior mesenteric artery (block arrow). (B) Four
weeks after PDT, the repeat CT scan at the same level suggested that
there was a clear tissue plane between the artery and the tumour (block
arrow), so rendering him suitable for surgery. As these scans were at the
level of maximum tumour involvement of the artery, they are not
exactly at the same level as the PDT necrosis, which is not visible on
scan (B).
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The median survival from treatment with PDT in this study was
similar to a comparable group of patients treated conventionally,
with a median survival from diagnosis of 15.5 months. However,
this was a highly selected non-randomised group who had both
prior and subsequent oncological treatments so conclusions on
survival advantage cannot be made. Nevertheless, it is of interest
that after PDT, one patient was re-staged and underwent a
successful R0 resection. This may have been related to volume
shrinkage due to resorption of necrotic tissue in the treated area of
cancer, as was documented in three cases in our earlier pancreatic
PDT study (Bown et al, 2002). In this regard, there is increasing
interest in the potential use of loco-regional treatments as part of a
multimodality approach to the management of pancreatic cancer.
Indeed, the recently presented SCALOP trial showed that
induction chemotherapy followed by chemoradiotherapy could
be given safely and effectively (Mukherjee et al, 2013). Radio-
frequency ablation has also been used in phase I settings, both via a
surgical and endoscopic approach but randomised trials are lacking
(Pezzilli et al, 2011; Arcidiacono et al, 2012). Irreversible
electroporation is an emerging non-thermal ablative technique
that uses electrodes, placed in the tumour, to deliver up to 3 kV of
direct current to induce the formation of nanoscale pores within
the cell membrane of the targeted tissue, causing apoptosis (Martin
et al, 2012; Narayanan et al, 2012). The US Food and Drug
Administration have recently approved the technique for use in the
pancreas.
In conclusion, we have shown in this phase I/II study that
verteporfin PDT-induced tumour necrosis in locally advanced
pancreatic cancer is feasible and safe. The low adverse event profile
does suggest that, alongside systemic treatments, there is a role for
further studies of PDT for the local treatment of pancreatic
adenocarcinoma or possibly for other focal pancreatic neoplasms
such as neuroendocrine tumours and pancreatic cystic neoplasms.
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